Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

SAN FRANCISCO, CA USA (UroToday.com) - Complete Title: GU Cancers Symposium 2014 - Session Highlights: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)

Novel mechanisms of steroid hormone production inhibition present exciting therapies for targeting castration-resistant prostate cancer. Orteronel (TAK-700) is a non-steroidal inhibitor of 17,20-lyase (similar to abiraterone), an enzyme integral to steroid production. Results from the ELM-PC5 trial of TAK-700 and prednisone for the treatment of progressive or docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC) were presented. The trial was performed at 260 centers from 42 countries across 5 continents. Disease progression was determined based on radiographic or PSA criteria. Patients were randomized 2:1 to orteronel and prednisone or placebo and prednisone, and primary endpoints examined include overall (OS) and radiographic progression-free survival (PFS).

gucancerssympalt thumbAmong the 1 099 patients randomized prior to trial accrual due to failure to meet its primary endpoint, median OS was 17.0 months (95% CI 15.2, 19.9) versus 15.2 months (95% CI 13.5, 16.9) (HR: 0.886 [95% CI: 0.739, 1.062]; P=0.1898) among patients treated with orteronel and placebo, respectively. Striking regional differences in OS were reported, with patients responding more favorably to orteronel than placebo in North America (OS 20.9 vs. 16.9 months) and the rest of the world (OS 15.3 vs. 10.1 months), but not in Europe (OS 18.3 vs. 17.3 months). One explanation posited to explain the regional differences in OS was the discrepant use of subsequent therapies in North America (26%), Europe (28%), and non-Europe/North America (8%).

Among the overall cohort, orteronel was associated with significantly improved radiographic PFS (median 8.3 months vs. 5.7 months; HR: 0.76 [95% CI: 0.653, 0.885]; P=0.00038). The most common side effects reported were nausea (16%), emesis (8%), fatigue (11%), and diarrhea (9%). Severe (≥ grade 3) toxicities include elevated amylase and lipase (< 1%) and fatigue (3%). The most common adverse event that led to discontinuation of therapy was GI toxicity. Overall, therapy was well tolerated and associated with minimal mineralocorticoid-related excess toxicity.

Highlights of a presentation by Robert Dreicer, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Cleveland Clinic, Cleveland, OH USA 

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

Click HERE to view the poster from this session

Click HERE to read the abstract for this session

View Full 2014 GU Cancers Symposium Coverage

 

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting